ZYDUSLIFE Zydus Lifesciences Ltd Product Launches Announcement 2024 - Clinical Trial Success Zydus Lifesciences has completed a Phase II(a) clinical trial of Usnoflast, an NLRP3 inhibitor, showing promise in treating Amyotrophic Lateral Sclerosis (ALS) with positive results on neurodegeneration biomarkers and ALS functional parameters..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Zydus Lifesciences Ltd